CRDF Stock Price, Cardiff Oncology, Inc. Quote, Chart

Market Summary

USD3.63-0.11

Market Closed

-2.94%

CRDF Stock Price

View Fullscreen

CRDF RSI Chart

CRDF Valuation

Market Cap

162.4M

Price/Earnings (Trailing)

-4.04

Price/Sales (Trailing)

332.68

Price/Free Cashflow

-5.3

CRDF Price/Sales (Trailing)

CRDF Profitability

Operating Margin

100.00%

Return on Equity

-66.07%

Return on Assets

-54.34%

Free Cashflow Yield

-18.86%

CRDF Fundamentals

CRDF Revenue

Revenue (TTM)

488.0K

Rev. Growth (Yr)

-78.19%

Rev. Growth (Qtr)

-67.79%

CRDF Earnings

Earnings (TTM)

-40.2M

Earnings Growth (Yr)

10.75%

Earnings Growth (Qtr)

-7.28%

Breaking Down CRDF Revenue

Last 7 days

7.1%

Last 30 days

-19.3%

Last 90 days

109.8%

Trailing 12 Months

114.2%

How does CRDF drawdown profile look like?

CRDF Financial Health

Current Ratio

5.91

CRDF Investor Care

Shares Dilution (1Y)

0.11%

Diluted EPS (TTM)

-0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	411.5K	437.0K	462.5K	488.0K
2022	438.5K	620.5K	1.0M	386.0K
2021	355.0K	383.0K	317.0K	365.5K
2020	266.3K	239.6K	323.9K	366.0K
2019	340.2K	298.2K	261.5K	260.3K
2018	510.5K	520.3K	485.3K	378.3K
2017	356.0K	354.0K	388.4K	505.4K
2016	306.0K	361.0K	392.0K	381.0K
2015	296.0K	289.0K	290.0K	313.0K
2014	251.0K	258.0K	271.0K	280.0K
2013	536.0K	543.0K	375.0K	259.0K
2012	202.6K	164.8K	321.8K	451.0K
2011	0	0	0	257.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cardiff Oncology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2023	pace gary w	bought	41,100	1.37	30,000	-
Nov 10, 2023	pace gary w	bought	22,491	0.98	22,950	-
Nov 25, 2022	erlander mark	bought	14,300	1.43	10,000	chief executive officer
Sep 19, 2022	white lale	bought	24,525	1.635	15,000	-
Sep 16, 2022	armitage james o	bought	20,233	1.5564	13,000	-
Sep 16, 2022	levine james e.	bought	46,710	1.557	30,000	chief financial officer
Sep 15, 2022	tannenbaum renee p	bought	17,168	1.7168	10,000	-
Sep 15, 2022	pace gary w	bought	256,500	1.71	150,000	-
Jul 05, 2022	white lale	acquired	75,030	2.6	28,858	-
Sep 21, 2021	pace gary w	bought	202,500	6.75	30,000	-

Which funds bought or sold CRDF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	ELKHORN PARTNERS LIMITED PARTNERSHIP	reduced	-40.46	111,000	208,000	0.15%
May 16, 2024	JANE STREET GROUP, LLC	added	233	354,111	386,211	-%
May 15, 2024	Royal Bank of Canada	added	3,118	80,000	80,000	-%
May 15, 2024	Squarepoint Ops LLC	new	-	93,519	93,519	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	185	256	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-25.11	77,257	122,644	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	3,648,820	3,648,820	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	2,320,670	2,320,670	-%
May 15, 2024	Laurion Capital Management LP	added	28.61	3,890,640	4,959,350	0.04%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-15,518	-	-%

Are Funds Buying or Selling CRDF?

Are funds buying CRDF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRDF

No. of Funds

Unveiling Cardiff Oncology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	acorn bioventures, l.p.	4.20%	1,946,762	SC 13G/A
Feb 14, 2023	caxton corp	2.2%	983,607	SC 13G/A
Feb 09, 2023	janus henderson group plc	0.0%	0	SC 13G/A
Jan 26, 2023	acorn bioventures, l.p.	6.38%	3,043,173	SC 13G
Jan 26, 2023	acorn bioventures, l.p.	6.38%	3,043,173	SC 13D/A
Jul 08, 2022	blackrock inc.	1.6%	671,967	SC 13G
Feb 14, 2022	avidity partners management lp	0%	0	SC 13G/A
Feb 14, 2022	corriente advisors, llc	0.0%	0	SC 13G/A
Feb 14, 2022	caxton corp	8.1%	3,479,340	SC 13G/A
Feb 09, 2022	state street corp	1.65%	693,445	SC 13G/A

Recent SEC filings of Cardiff Oncology, Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 08, 2024	8-K	Current Report
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Cardiff Oncology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cardiff Oncology, Inc. News

Latest updates

Cardiff Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-67.8%	205,000	636,500	1,068,000	1,053,000	940,000	699,000	458,000	253,000	130,000	167,500	70,000	71,000	57,000	119,000	136,000	43,000	68,000	76,870	51,687	69,761	62,021
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	6.2%	11,138,000	10,488,000	10,961,000	12,316,000	12,135,000	9,520,000	9,086,000	10,534,000	11,148,000	9,659,000	7,084,000	6,957,000	5,514,000	6,616,000	4,499,000	4,145,000	4,192,000	4,381,873	4,259,163	4,258,307	4,023,784
S&GA Expenses	14.9%	3,130,000	2,725,000	2,939,000	4,296,000	3,083,000	3,078,000	3,077,000	3,086,000	3,940,000	3,835,000	2,930,000	2,838,000	2,235,000	3,417,500	1,644,000	1,669,000	1,486,000	1,517,400	1,440,339	1,427,967	1,375,185
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	1,000	-	1,000	-	-	1,000	-	-	-	1,000	-	-	-	1,000	-	-	-	800
Net Income	-7.3%	-10,017,000	-9,337,000	-9,731,000	-11,150,000	-11,223,000	-8,697,000	-8,571,000	-10,443,000	-10,993,000	-9,442,000	-6,913,000	-6,757,000	-5,179,000	-6,597,000	-4,497,000	-4,124,000	-4,089,000	-4,242,536	-4,141,549	-4,125,303	-3,904,771
Net Income Margin	2.9%	-82.45	-84.92	-88.22	-90.71	-94.61	-100	-39.12	-60.90	-77.78	-77.40	-80.27	-60.13	-	-	-	-	-	-	-	-	-
Free Cashflow	-9.4%	-7,820,000	-7,147,000	-8,272,000	-7,383,000	-8,667,000	-9,465,000	-7,934,000	-7,007,000	-10,420,000	-7,497,000	-5,563,000	-4,301,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.3%	74.00	82.00	88.00	97.00	107	116	124	131	139	150	141	144	130	135	39.00	30.00	12.00	13.00	12.00	14.00	15.00
Current Assets	-9.6%	70.00	77.00	84.00	93.00	102	111	120	127	136	146	138	143	129	133	38.00	29.00	10.00	11.00	10.00	12.00	12.00
Cash Equivalents	-13.8%	19.00	22.00	15.00	19.00	15.00	16.00	19.00	21.00	20.00	12.00	13.00	11.00	15.00	131	36.00	28.00	9.00	10.00	9.00	11.00	11.00
Net PPE	-3.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Liabilities	10.5%	13.00	12.00	11.00	11.00	10.00	10.00	10.00	11.00	9.00	9.00	8.00	5.00	5.00	7.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00
Current Liabilities	13.4%	12.00	10.00	9.00	9.00	8.00	8.00	8.00	8.00	7.00	7.00	5.00	5.00	4.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00
Shareholder's Equity	-12.7%	61.00	70.00	78.00	87.00	97.00	106	113	120	130	140	134	139	125	128	34.00	24.00	6.00	7.00	7.00	9.00	10.00
Retained Earnings	-2.7%	-348	-339	-330	-320	-309	-298	-289	-281	-270	-259	-250	-243	-236	-231	-224	-220	-212	-208	-204	-200	-196
Additional Paid-In Capital	0.1%	410	409	408	407	406	405	404	403	402	401	385	384	363	362	261	248	220	217	212	211	208
Shares Outstanding	0.1%	45.00	45.00	45.00	45.00	45.00	45.00	43.00	43.00	43.00	42.00	39.00	38.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	64.00	-	-	-	94.00	-	-	-	259	-	-	-	104	-	-	-	14.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-8.4%	-7,740	-7,139	-7,957	-7,132	-8,659	-9,390	-7,486	-6,695	-10,249	-7,390	-5,465	-4,301	-5,884	-5,124	-3,526	-4,291	-3,374	-3,276	-3,187	-3,443	-3,360
Share Based Compensation	23.7%	1,124	909	955	1,581	1,064	1,012	1,037	1,055	1,152	990	940	1,036	268	944	362	282	177	270	266	149	200
Cashflow From Investing	-65.8%	4,636	13,561	3,821	11,484	7,329	7,020	5,163	7,608	18,358	-8,794	8,049	-19,005	-111,698	-57.00	-154	-	-	-	-62.35	-	-5.27
Cashflow From Financing	-	107	-	-	-	-	-	75.00	-	-	14,962	-	19,225	1,263	99,757	12,330	22,769	2,456	4,440	1,491	2,904	3,242

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRDF Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Royalties	$ 205	$ 83
Costs and expenses:
Research and development	8,008	9,052
Selling, general and administrative	3,130	3,083
Total operating expenses	11,138	12,135
Loss from operations	(10,933)	(12,052)
Interest income, net	926	940
Other income (expense), net	(4)	(111)
Total other income (expense), net	922	829
Net loss	(10,011)	(11,223)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6)	(6)
Net loss attributable to common stockholders	$ (10,017)	$ (11,229)
Net loss per common share - basic (in dollars per share)	$ (0.22)	$ (0.25)
Net loss per common share - diluted (in dollars per share)	$ (0.22)	$ (0.25)
Weighted-average shares outstanding - basic (in shares)	44,678	44,677
Weighted-average shares outstanding - diluted (in shares)	44,678	44,677

CRDF Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 18,658	$ 21,655
Short-term investments	48,529	53,168
Accounts receivable and unbilled receivable	393	288
Prepaid expenses and other current assets	2,410	2,301
Total current assets	69,990	77,412
Property and equipment, net	1,199	1,238
Operating lease right-of-use assets	1,574	1,708
Other assets	1,275	1,279
Total Assets	74,038	81,637
Current liabilities:
Accounts payable	5,191	1,966
Accrued liabilities	5,956	7,783
Operating lease liabilities	696	691
Total current liabilities	11,843	10,440
Operating lease liabilities, net of current portion	1,301	1,458
Total Liabilities	13,144	11,898
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, 20,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at March 31, 2024 and December 31, 2023 with liquidation preference of $1,074 and $1,068 at March 31, 2024 and December 31, 2023, respectively (Note 5)	0	0
Common stock, $0.0001 par value, 150,000 shares authorized; 44,710 and $44,677 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	409,781	409,343
Accumulated other comprehensive loss	(132)	(67)
Accumulated deficit	(348,759)	(339,541)
Total stockholders’ equity	60,894	69,739
Total liabilities and stockholders’ equity	$ 74,038	$ 81,637

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CEO	Dr. Mark Erlander Ph.D.
WEBSITE	cardiffoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Cardiff Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Cardiff Oncology, Inc.? What does CRDF stand for in stocks?

CRDF is the stock ticker symbol of Cardiff Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cardiff Oncology, Inc. (CRDF)?

As of Fri May 17 2024, market cap of Cardiff Oncology, Inc. is 162.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRDF stock?

You can check CRDF's fair value in chart for subscribers.

What is the fair value of CRDF stock?

You can check CRDF's fair value in chart for subscribers. The fair value of Cardiff Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cardiff Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRDF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cardiff Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether CRDF is over valued or under valued. Whether Cardiff Oncology, Inc. is cheap or expensive depends on the assumptions which impact Cardiff Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRDF.

What is Cardiff Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CRDF's PE ratio (Price to Earnings) is -4.04 and Price to Sales (PS) ratio is 332.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRDF PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cardiff Oncology, Inc.'s stock?

In the past 10 years, Cardiff Oncology, Inc. has provided -0.351 (multiply by 100 for percentage) rate of return.